Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy

被引：28

作者：

Yamada, Takanobu ^{[1
]}

Hayashi, Tsutomu ^{[1
]}

Inokuchi, Yasuhiro ^{[2
]}

Hayashi, Kimihiro ^{[2
]}

Watanabe, Hayato ^{[1
]}

Komori, Keisuke ^{[1
]}

Kano, Kazuki ^{[1
]}

Shimoda, Yota ^{[1
]}

Fujikawa, Hirohito ^{[1
]}

Shiozawa, Manabu ^{[1
]}

Morinaga, Soichiro ^{[1
]}

Rino, Yasushi ^{[3
]}

Masuda, Munetaka ^{[3
]}

Ogata, Takashi ^{[1
]}

Oshima, Takashi ^{[1
]}

机构：

[1] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, 2-3-2 Nakano Asahi, Yokohama, Kanagawa, Japan

[2] Kanagawa Canc Ctr, Dept Gastroenterol, Yokohama, Kanagawa, Japan

[3] Yokohama City Univ, Dept Surg, Yokohama, Kanagawa, Japan

来源：

TARGETED ONCOLOGY | 2020年 / 15卷 / 03期

关键词：

IMMUNE CHECKPOINT BLOCKADE; SOLID TUMORS; CELL CARCINOMA; GUIDELINES; OUTCOMES; MARKER;

D O I：

10.1007/s11523-020-00716-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background In 2017, nivolumab monotherapy was shown to be effective as third- or later-line therapy in patients with advanced gastric or gastroesophageal junction cancer. Objective In this study, we investigated the relationship between the neutrophil-to-lymphocyte ratio (NLR) and the outcomes of nivolumab monotherapy in patients with gastric or gastroesophageal junction cancer. Patients and Methods The long-term outcomes and treatment responses to nivolumab monotherapy were assessed in patients with gastric or gastroesophageal junction cancer. We compared patients with a NLR > 2.5 and those with a NLR <= 2.5 at the time of starting nivolumab monotherapy. Results The proportion of patients who have received three or more regimens was higher in the NLR > 2.5 group than in the NLR <= 2.5 group. The disease control rate was significantly worse in the NLR > 2.5 group than in the NLR <= 2.5 group (23% and 46%, respectively; p = 0.044). Overall survival was significantly better in the NLR <= 2.5 group than in the NLR > 2.5 group. Multivariate analysis showed that the macroscopic type, primary site resection, and the NLR were independent prognostic factors for overall survival (hazard ratio [95% confidence interval], 2.586 [1.286-5.203], 0.473 [0.260-0.861], and 1.736 [1.007-2.992], respectively). Conclusions This study demonstrates that the NLR is an independent prognostic factor in patients with gastric or gastroesophageal junction cancer treated with nivolumab monotherapy. Careful attention must be paid when nivolumab monotherapy is used to treat patients with gastric cancer with a NLR > 2.5.

引用

页码：317 / 325

页数：9

共 33 条

[1] Gastric Cancer, Version 3.2016 [J].

Ajani, Jaffer A. ;

D'Amico, Thomas A. ;

Almhanna, Khaldoun ;

Bentrem, David J. ;

Chao, Joseph ;

Das, Prajnan ;

Denlinger, Crystal S. ;

Fanta, Paul ;

Farjah, Farhood ;

Fuchs, Charles S. ;

Gerdes, Hans ;

Gibson, Michael ;

Glasgow, Robert E. ;

Hayman, James A. ;

Hochwald, Steven ;

Hofstetter, Wayne L. ;

Ilson, David H. ;

Jaroszewski, Dawn ;

Johung, Kimberly L. ;

Keswani, Rajesh N. ;

Kleinberg, Lawrence R. ;

Korn, W. Michael ;

Leong, Stephen ;

Linn, Catherine ;

Lockhart, A. Craig ;

Ly, Quan P. ;

Mulcahy, Mary F. ;

Orringer, Mark B. ;

Perry, Kyle A. ;

Poultsides, George A. ;

Scott, Walter J. ;

Strong, Vivian E. ;

Washington, Mary Kay ;

Weksler, Benny ;

Willett, Christopher G. ;

Wright, Cameron D. ;

Zelman, Debra ;

McMillian, Nicole ;

Sundar, Hema .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (10) :1286-1312

[2] Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors [J].

Ameratunga, Malaka ;

Chenard-Poirier, Maxime ;

Moreno Candilejo, Irene ;

Pedregal, Manuel ;

Lui, Andrew ;

Dolling, David ;

Aversa, Caterina ;

Garces, Alvaro Ingles ;

Ang, Joo Ern ;

Banerji, Udai ;

Kaye, Stan ;

Gan, Hui ;

Doger, Bernard ;

Moreno, Victor ;

de Bono, Johann ;

Lopez, Juanita .

EUROPEAN JOURNAL OF CANCER, 2018, 89 :56-63

[3] Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer [J].

Bagley, Stephen J. ;

Kothari, Shawn ;

Aggarwal, Charu ;

Bauml, Joshua M. ;

Alley, Evan W. ;

Evans, Tracey L. ;

Kosteva, John A. ;

Ciunci, Christine A. ;

Gabriel, Peter E. ;

Thompson, Jeffrey C. ;

Stonehouse-Lee, Susan ;

Sherry, Victoria E. ;

Gilbert, Elizabeth ;

Eaby-Sandy, Beth ;

Mutale, Faith ;

DiLullo, Gloria ;

Cohen, Roger B. ;

Vachani, Anil ;

Langer, Corey J. .

LUNG CANCER, 2017, 106 :1-7

[4] Comprehensive molecular characterization of gastric adenocarcinoma [J].

Bass, Adam J. ;

Thorsson, Vesteinn ;

Shmulevich, Ilya ;

Reynolds, Sheila M. ;

Miller, Michael ;

Bernard, Brady ;

Hinoue, Toshinori ;

Laird, Peter W. ;

Curtis, Christina ;

Shen, Hui ;

Weisenberger, Daniel J. ;

Schultz, Nikolaus ;

Shen, Ronglai ;

Weinhold, Nils ;

Keiser, David P. ;

Bowlby, Reanne ;

Sipahimalani, Payal ;

Cherniack, Andrew D. ;

Getz, Gad ;

Liu, Yingchun ;

Noble, Michael S. ;

Pedamallu, Chandra ;

Sougnez, Carrie ;

Taylor-Weiner, Amaro ;

Akbani, Rehan ;

Lee, Ju-Seog ;

Liu, Wenbin ;

Mills, Gordon B. ;

Yang, Da ;

Zhang, Wei ;

Pantazi, Angeliki ;

Parfenov, Michael ;

Gulley, Margaret ;

Piazuelo, M. Blanca ;

Schneider, Barbara G. ;

Kim, Jihun ;

Boussioutas, Alex ;

Sheth, Margi ;

Demchok, John A. ;

Rabkin, Charles S. ;

Willis, Joseph E. ;

Ng, Sam ;

Garman, Katherine ;

Beer, David G. ;

Pennathur, Arjun ;

Raphael, Benjamin J. ;

Wu, Hsin-Ta ;

Odze, Robert ;

Kim, Hark K. ;

Bowen, Jay .

NATURE, 2014, 513 (7517) :202-209

[5] Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis [J].

Benedict Sacdalan, Danielle ;

Anne Lucero, Josephine ;

Lee Sacdalan, Dennis .

ONCOTARGETS AND THERAPY, 2018, 11 :955-965

[6] Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab [J].

Bilen, Mehmet Asim ;

Dutcher, Giselle Marie Almeida ;

Liu, Yuan ;

Ravindranathan, Deepak ;

Kissick, Haydn T. ;

Carthon, Bradley C. ;

Kucuk, Omer ;

Harris, Wayne B. ;

Master, Viraj A. .

CLINICAL GENITOURINARY CANCER, 2018, 16 (03) :E563-E575

[7] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[8] Immune Suppression by Neutrophils in HIV-1 Infection: Role of PD-L1/PD-1 Pathway [J].

Bowers, Nathan L. ;

Helton, E. Scott ;

Huijbregts, Richard P. H. ;

Goepfert, Paul A. ;

Heath, Sonya L. ;

Hel, Zdenek .

PLOS PATHOGENS, 2014, 10 (03)

[9] Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab [J].

Capone, Mariaelena ;

Giannarelli, Diana ;

Mallardo, Domenico ;

Madonna, Gabriele ;

Festino, Lucia ;

Grimaldi, Antonio Maria ;

Vanella, Vito ;

Simeone, Ester ;

Paone, Miriam ;

Palmieri, Giuseppe ;

Cavalcanti, Ernesta ;

Caraco, Corrado ;

Ascierto, Paolo Antonio .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[10] Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer [J].

Choi, Yeonjoo ;

Kim, Jin Won ;

Nam, Kyung Han ;

Han, Song-Hee ;

Kim, Ji-Won ;

Ahn, Sang-Hoon ;

Park, Do Joong ;

Lee, Keun-Wook ;

Lee, Hye Seung ;

Kim, Hyung-Ho .

GASTRIC CANCER, 2017, 20 (04) :602-611

← 1 2 3 4 →